Drug profile · INN
taliglucerase alfa
ELELYSO
taliglucerase alfa (ELELYSO) is a glucocerebroside hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — taliglucerase alfa
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
taliglucerase alfa (ELELYSO) is a glucocerebroside hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocerebroside hydrolytic enzyme
Primary target: Glucocerebroside
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is taliglucerase alfa?
taliglucerase alfa (ELELYSO) is a glucocerebroside hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for taliglucerase alfa?
ELELYSO is a marketed brand name for taliglucerase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of taliglucerase alfa?
taliglucerase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.